EyRIS: AI for Eye-Disease Screening Custom Case Solution & Analysis

Section 1: Evidence Brief

Financial Metrics

Series A Funding: Five million Singapore dollars raised in 2019 to support international expansion and product development.
Revenue Model: Transaction-based fee per scan or annual subscription license for high-volume institutions.
Cost Structure: Significant upfront investment in research and development with low marginal costs per additional screening.
Market Valuation: Estimated growth in the global diabetic retinopathy market reaching over ten billion dollars by 2025.

Operational Facts

Technology: SELENA+ deep learning system trained on nearly five hundred thousand fundus images from diverse ethnic groups.
Accuracy: Sensitivity and specificity rates exceeding ninety percent for detecting referable diabetic retinopathy.
Deployment: Cloud-based platform allowing for remote image processing and rapid diagnostic feedback within minutes.
Partnerships: Collaboration with the Singapore Eye Research Institute and the National University of Singapore for intellectual property.

Stakeholder Positions

Dr. Wong Tien Yin: Lead researcher and founder who prioritizes clinical excellence and global health impact.
Steven Siew: Chief Executive Officer focused on commercial viability and scaling the sales pipeline across Asia and Europe.
Public Health Authorities: Interested in reducing the burden on specialized ophthalmologists through automated primary care screening.
Optometrists and General Practitioners: Potential users who require seamless integration into existing clinical workflows.

Information Gaps

Detailed breakdown of customer acquisition costs across different geographic territories.
Specific churn rates for early pilot programs in international markets.
Exact maintenance costs for maintaining server infrastructure in regions with strict data residency laws.
Competitor pricing data for emerging AI diagnostic startups in the United States and China.

Section 2: Strategic Analysis

Core Strategic Question

How can EyRIS transition from a research-backed entity into a profitable global leader in AI diagnostics while overcoming regulatory fragmentation and high entry barriers?

Structural Analysis

The diagnostic imaging industry is shifting from hardware-centric models to software-defined intelligence. Using the Value Chain lens, the primary value has moved from the fundus camera to the interpretation of the image. The bargaining power of buyers is moderate in private healthcare but high in public health tenders. The threat of substitutes is low due to the high clinical validation required for AI, but the threat of new entrants is rising as more academic institutions attempt to commercialize similar algorithms.

Strategic Options

Option 1: Direct B2B Sales to Large Hospital Networks
- Rationale: High-volume contracts provide stable cash flow and deep clinical integration.
- Trade-offs: Long sales cycles and heavy reliance on hospital IT infrastructure.
- Resource Requirements: Dedicated enterprise sales team and technical support staff.
Option 2: Partnership with Hardware Manufacturers (OEM)
- Rationale: Embed SELENA+ into fundus cameras at the point of manufacture to reach a global footprint instantly.
- Trade-offs: Lower margins per scan and loss of direct relationship with the end-user.
- Resource Requirements: Legal and technical teams to manage API integrations and licensing agreements.
Option 3: Public Health Screening (B2G)
- Rationale: National-level contracts provide massive scale and validate the technology for other markets.
- Trade-offs: Political risk and pricing pressure from government budget constraints.
- Resource Requirements: Government relations experts and large-scale data management capabilities.

Preliminary Recommendation

EyRIS should prioritize Option 2. Partnering with major camera manufacturers like Topcon or Zeiss allows the company to scale without the prohibitive cost of building a global sales force. This path secures the software as a standard feature in diagnostic hardware, creating a high barrier to entry for competitors.

Section 3: Implementation Roadmap

Critical Path

Month 1 to 3: Finalize API documentation and integration protocols for the top three fundus camera brands.
Month 4 to 6: Secure CE Mark and FDA clearance for the updated software version to enable expansion into Western markets.
Month 7 to 9: Launch pilot programs with two major international optical retail chains to demonstrate the recurring revenue model.
Month 10 to 12: Transition to a tiered pricing structure that includes a base license plus a fee per screening.

Key Constraints

Regulatory Approval: Delays in FDA or local health authority certifications will stall market entry in key territories.
Data Privacy: Compliance with GDPR and other regional data protection laws requires significant localized server investment.
Physician Acceptance: Resistance from ophthalmologists who may view AI as a threat to their professional relevance or income.

Risk-Adjusted Implementation Strategy

The strategy focuses on a phased rollout. Initially, the company will target regions with existing regulatory alignment to Singapore, such as parts of Southeast Asia and the Middle East. Contingency plans include a localized version of the software that can run on-premise to bypass cloud connectivity issues in developing markets. A clinical education program will be launched simultaneously to position the AI as a tool for triage rather than a replacement for specialized doctors.

Section 4: Executive Review and BLUF

BLUF

EyRIS must pivot from a standalone software provider to an embedded technology partner. The current strategy of direct sales is too slow to capture the rapidly closing window of market opportunity. By integrating the AI directly into the hardware of camera manufacturers, EyRIS can achieve global scale with minimal capital expenditure. The primary objective is to become the industry standard for eye screening before competitors with larger data sets emerge from the United States or China. Success depends on rapid regulatory approval and the ability to maintain high accuracy across diverse populations. Failure to secure these partnerships within the next eighteen months will result in the technology becoming a niche product rather than a global platform.

Dangerous Assumption

The analysis assumes that hardware manufacturers are willing to share their profit margins with a third-party software provider rather than developing their own in-house AI capabilities or acquiring a smaller competitor.

Unaddressed Risks

Liability Risk: The probability of a false negative leading to legal action against the company is moderate, but the consequence is a total loss of brand trust and potential bankruptcy.
Technological Obsolescence: The rapid advancement in smartphone-based fundus photography could make expensive traditional cameras and their associated software less relevant in the long term.

Unconsidered Alternative

The team did not fully explore a B2C model where patients could upload images directly from portable devices. While clinical accuracy is currently lower for such devices, the rapid improvement in mobile lens technology could disrupt the professional screening market entirely.